Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Apalutamide in Intermediate to High Risk Prostate Cancer
NCT03124433Phase 2Completed
- Sponsor
- Singapore General Hospital
- Start
- Jun 2017
- Primary completion
- Aug 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of apalutamide in prostate cancer (PCa), sponsored by Singapore General Hospital. Started Jun 2017; status: completed.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03124433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03124433.